Author

C. Ueki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

G. Tsujimoto· 2 shared K. Yoshikawa· 2 shared N. Okada· 2 shared C. Takahashi· 1 shared H. Muranaka· 1 shared M. Shimazaki· 1 shared R. Ito· 1 shared S. Kohno· 1 shared

Activity by Year

2022-2022 · peak 2/yr

Co-Author Collaboration Network

8 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Tsujimoto

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NFYA promotes the anti-tumor effects of gluconeogenesis in hepatocellular carcinoma through the regulation of PCK1 expression

G. Tsujimoto, R. Ito, K. Yoshikawa, C. Ueki, N. Okada

This study shows that NFYAv2 promotes anti-tumor effects in HCC by upregulating PCK1, leading to increased ROS and energy crisis, and suggests it as a potential therapeutic target.

bioRxiv · Jun 30, 2022Cancer Biology

NFYA promotes the malignant behavior of triple-negative breast cancer through the regulation of lipid metabolism

N. Okada, C. Ueki, M. Shimazaki, G. Tsujimoto, S. Kohno, H. Muranaka, K. Yoshikawa, C. Takahashi

The paper shows NFYAv1 promotes TNBC malignancy by enhancing lipid metabolism, and targeting this axis could be a therapeutic strategy.

bioRxiv · May 26, 2022 · PreprintCancer Biology